Citations

Clear

79 citation(s) found for "Shang, Lu".

LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins
Wei, Wei‐Qi, Li, Xiaohui , Feng, QiPing , Kubo, Michiaki , Peissig, Peggy , Karlson, Elizabeth W. , Jarvik, Gail P. , Shang, Ning , Larson, Eric , Shaffer, Christian M., Maeda, Shiro , Horikoshi, Momoko , Ritchie, Marylyn D. , Larson, Eric B. , Crosslin, David R. , Bland, Harris T. , Pacheco, Jennifer A. , Rasmussen‐Torvik, Laura J. , Cox, Nancy J. , Wilke, Russell A. , Rotter, Jerome I. , Momozawa, Yukihide , Roden, Dan M. , Krauss, Ronald M. , Denny, Joshua C. , Denny, Joshua C , Bland, Sarah T , Jarvik, Gail P , Wei, Wei-Qi , Rotter, Jerome I , Pacheco, Jennifer A , Kullo, Iftikhar J. , Lee, Ming Ta Michael , Edwards, Todd L. , Mosley, Jonathan D , Williams, Marc S , Cronkite, David , Hripcsak, George , Stein, Christoph , Roden, Dan M. , Feng, Qiping , Rasmussen-Torvik, Laura J

Mayo Clinic

Circulation | April 27, 2018 | Volume: 138 | Issue: 17 | Pages: 1839-1849

10.1161/circulationaha.117.031356 | PMID 29703846 Get It

Background: Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and the incidence of CHD, additional events occur despite statin therapy in some individuals. The genetic determinants of this residual cardiovascular risk remain unknown. Methods: We performed a 2-stage genome-wide association study of CHD events during statin therapy. We first identified 3099 cases who experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7681 controls without CHD events during comparable intensity and duration of statin therapy from 4 sites in the Electronic Medical Records and Genomics Network. We then sought replication of candidate variants in another 160 cases and 1112 controls from a fifth Electronic Medical Records and Genomics site, which joined the network after the initial genome-wide association study. Finally, we performed a phenome-wide association study for other traits linked to the most significant locus. Results: The meta-analysis identified 7 single nucleotide polymorphisms at a genome-wide level of significance within the LPA/PLG locus associated with CHD events on statin treatment. The most significant association was for an intronic single nucleotide polymorphism within LPA/PLG (rs10455872; minor allele frequency, 0.069; odds ratio, 1.58; 95% confidence interval, 1.35–1.86; P =2.6×10 − 10 ). In the replication cohort, rs10455872 was also associated with CHD events (odds ratio, 1.71; 95% confidence interval, 1.14–2.57; P =0.009). The association of this single nucleotide polymorphism with CHD events was independent of statin-induced change in low-density lipoprotein cholesterol (odds ratio, 1.62; 95% confidence interval, 1.17–2.24; P =0.004) and persisted in individuals with low-density lipoprotein cholesterol ≤70 mg/dL (odds ratio, 2.43; 95% confidence interval, 1.18–4.75; P =0.015). A phenome-wide association study supported the effect of this region on coronary heart disease and did not identify noncardiovascular phenotypes. Conclusions: Genetic variations at the LPA locus are associated with CHD events during statin therapy independently of the extent of low-density lipoprotein cholesterol lowering. This finding provides support for exploring strategies targeting circulating concentrations of lipoprotein(a) to reduce CHD events in patients receiving statins.
Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway
Qin, Chuan , Fan, Wen-Hui, Shang, Ke , Murugan, Madhuvika , Wu, Long‐Jun , Wang, Wei , Tian, Dai‐Shi , Wu, Long-Jun , Tian, Dai-Shi , Liu, Qian

Mayo Clinic

Stroke | November 7, 2017 | Volume: 48 | Issue: 12 | Pages: 3336-3346

10.1161/strokeaha.117.018505 | PMID 29114096 Get It

Background and Purpose— White matter (WM) ischemic injury, a major neuropathological feature of cerebral small vessel diseases, is an important cause of vascular cognitive impairment in later life. The pathogenesis of demyelination after WM ischemic damage are often accompanied by microglial activation. Fingolimod (FTY720) was approved for the treatment of multiple sclerosis for its immunosuppression property. In this study, we evaluated the neuroprotective potential of FTY720 in a WM ischemia model. Methods— Chronic WM ischemic injury model was induced by bilateral carotid artery stenosis. Cognitive function, WM integrity, microglial activation, and potential pathway involved in microglial polarization were assessed after bilateral carotid artery stenosis. Results— Disruption of WM integrity was characterized by demyelination in the corpus callosum and disorganization of Ranvier nodes using Luxol fast blue staining, immunofluorescence staining, and electron microscopy. In addition, radial maze test demonstrated that working memory performance was decreased at 1-month post–bilateral carotid artery stenosis–induced injury. Interestingly, FTY720 could reduce cognitive decline and ameliorate the disruption of WM integrity. Mechanistically, cerebral hypoperfusion induced microglial activation, production of associated proinflammatory cytokines, and priming of microglial polarization toward the M1 phenotype, whereas FTY720 attenuated microglia-mediated neuroinflammation after WM ischemia and promoted oligodendrocytogenesis by shifting microglia toward M2 polarization. FTY720’s effect on microglial M2 polarization was largely suppressed by selective signal transducer and activator of transcription 3 (STAT3) blockade in vitro, revealing that FTY720-enabled shift of microglia from M1 to M2 polarization state was possibly mediated by STAT3 signaling. Conclusions— Our study suggested that FTY720 might be a potential therapeutic drug targeting brain inflammation by skewing microglia toward M2 polarization after chronic cerebral hypoperfusion.
Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States
Garrett, Giorgia L., Boscardin, John, Lloyd, Amanda Abramson, Ahmed, Rehana L. , Anthony, Tiffany, Bibee, Kristin , Breithaupt, Andrew, Cannon, Jennifer, Chen, Amy , Cheng, J , Fuxench, Zelma C. Chiesa , Colegio, Oscar R. , Curiel‐Lewandrowski, Clara , Guzzo, Christina A. Del, Disse, Max, Dowd, Margaret , Eilers, Robert, Ortiz, Arisa , Golden, Spring, Graves, Michael S., Griffin, John R., Hopkins, R. Samuel, Huang, Conway C. , Jambusaria, Anokhi, Jennings, Thomas , Khetarpal, Shilpi , Kim, Chang-Hyun , Klintmalm, Göran B. , Konicke, Kathryn, Koyfman, Shlomo A. , Lam, Charlene , Leitenberger, Justin J. , Loh, Tiffany Y. , Lowenstein, Stefan E. , Madankumar, Reshmi, Moreau, Jacqueline F. , Nijhawan, Rajiv I. , Ochoa, Shari A. , Olasz, Edit , Otchere, Elaine , Otley, Clark C. , Oulton, Jeremy, Patel, Parth H., Prabhu, Arpan V. , Pugliano‐Mauro, Melissa , Schmults, Chrysalyne D. , Schram, Sarah E., Shih, Allen F. , Shin, Thuzar M. , Soon, Seaver L. , Stein, Jennifer , Sternhell‐Blackwell, Kara, Taylor, Stan, Vidimos, Allison T. , Wu, Peggy A. , Zajdel, Nicholas, Zelac, Daniel E. , Arron, Sarah T. , Kim, Changhyun, Ochoa, Shari, Otley, Clark, Blanc, Paul David , Boscardin, W. John , Morris, Caroline Rose , Bae, Gordon Hyeonjin , Jambusaria‐Pahlajani, Anokhi , Jiang, Shang I. Brian , Karia, Pritesh S. , Lee, Peter, Patel, Vishal Anil , Soriano, Teresa T. , Srivastava, Divya , Nj, Zajdel

Mayo Clinic

JAMA Dermatology | January 17, 2017 | Volume: 153 | Issue: 3 | Pages: 296

10.1001/jamadermatol.2016.4920 | PMID 28097368 Get It

Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer
Tice, Jeffrey A. , Miglioretti, Diana L. , Li, Chin-Shang, Vachon, Celine M. , Gard, Charlotte C. , Vachon, Celine M. , Kerlikowske, Karla , Miglioretti, Diana L

Mayo Clinic

Journal of Clinical Oncology | August 17, 2015 | Volume: 33 | Issue: 28 | Pages: 3137-3143

10.1200/jco.2015.60.8869 | PMID 26282663 Get It

Purpose Women with proliferative breast lesions are candidates for primary prevention, but few risk models incorporate benign findings to assess breast cancer risk. We incorporated benign breast disease (BBD) diagnoses into the Breast Cancer Surveillance Consortium (BCSC) risk model, the only breast cancer risk assessment tool that uses breast density. Methods We developed and validated a competing-risk model using 2000 to 2010 SEER data for breast cancer incidence and 2010 vital statistics to adjust for the competing risk of death. We used Cox proportional hazards regression to estimate the relative hazards for age, race/ethnicity, family history of breast cancer, history of breast biopsy, BBD diagnoses, and breast density in the BCSC. Results We included 1,135,977 women age 35 to 74 years undergoing mammography with no history of breast cancer; 17% of the women had a prior breast biopsy. During a mean follow-up of 6.9 years, 17,908 women were diagnosed with invasive breast cancer. The BCSC BBD model slightly overpredicted risk (expected-to-observed ratio, 1.04; 95% CI, 1.03 to 1.06) and had modest discriminatory accuracy (area under the receiver operator characteristic curve, 0.665). Among women with proliferative findings, adding BBD to the model increased the proportion of women with an estimated 5-year risk of 3% or higher from 9.3% to 27.8% (P < .001). Conclusion The BCSC BBD model accurately estimates women's risk for breast cancer using breast density and BBD diagnoses. Greater numbers of high-risk women eligible for primary prevention after BBD diagnosis are identified using the BCSC BBD model.
CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome
Cataliotti, Alessandro , Pascale, E. de, Giordano, Gelsomina, Jougasaki, Michihisa , Costello, Lisa C., Boerrigter, Guido, Tsuruda, Toshihiro , Belluardo, Paola, Lee, Shang-Chiun, Huntley, Brenda K., Sandberg, Sharon M., Burnett, John C. , Giordano, Mauro , Castellino, Pietro , Malatino, Lorenzo

Mayo Clinic

American Journal of Physiology-Renal Physiology | March 3, 2015 | Volume: 283 | Issue: 3 | Pages: F464-F472

10.1152/ajprenal.00372.2001 | PMID 12167597 Get It

C-type natriuretic peptide (CNP) possesses well-established cardiovascular properties. Although present in the mammalian kidney, CNP production in human kidney and its modulation in human renal disease remain less defined. We investigated the presence of CNP in normal human kidney and in patients with nephrotic syndrome (NS). We also addressed whether or not a low-protein diet (LPD) alters plasma CNP and urinary CNP excretion in NS. In situ hybridization studies demonstrated CNP mRNA expression in tubular cells and glomeruli of normal human kidneys. CNP immunoreactivity was positive in proximal, distal, and medullary collecting duct tubular cells in both controls and patients with NS. The ratios of plasma CNP and urinary CNP to creatinine were significantly higher in patients with NS compared with controls. Urinary CNP, but not plasma CNP, was significantly lowered in patients with NS after an LPD. Similarly, the ratios of urinary protein to creatinine and urinary albumin to creatinine, but not urinary guanosine 3′,5′-cyclic monophosphate to creatinine, decreased significantly with an LPD. These data confirm and extend previous reports and demonstrate for the first time the presence of CNP in human kidney with NS. We also report increased plasma CNP concentration and urinary CNP excretion in NS patients and a significant reduction of CNP excretion with an LPD. Our findings demonstrate that CNP metabolism is altered in patients with NS and support the hypothesis that activation of renal CNP can be partially offset by an LPD. These results underscore that the beneficial effect of an LPD on protein excretion is paralleled by a substantial reduction in intrarenal CNP release.
CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
Burington, Bart, Peng, Yue , Shi, Xiaoyan , Advani, Ranjana H. , Lau, Jeffrey , Stinson, Susanna, Stinson, Jeremy, Januario, Thomas, Vos, Sven de , Ansell, Stephen M. , Forero‐Torres, Andres , Fedorowicz, Grazyna, Yang, Teddy , Elkins, Kristi , Du, Changchun, Mohan, Sankar, Modrušan, Zora , Seshagiri, Somasekar , Yu, Shang‐Fan , Pandita, Ajay , Koeppen, Hartmut , French, Dorothy, Polson, Andrew G. , Offringa, Rienk , Whiting, Nancy, Ebens, Allen , Dornan, David, Tan, Jenille , Yu, Nancy , Advani, Ranjana H , Modrusan, Zora

Mayo Clinic

Science Translational Medicine | March 16, 2011 | Volume: 3 | Issue: 74 | Pages: No page available

10.1126/scitranslmed.3001620 | PMID 21411738 Get It

A 15-gene expression signature predicts whether a patient with diffuse large B cell lymphoma will respond to dacetuzumab, a therapeutic antibody.
Mutation in Glycerol-3-Phosphate Dehydrogenase 1–Like Gene ( GPD1-L ) Decreases Cardiac Na + Current and Causes Inherited Arrhythmias
London, Barry , Michalec, Michael, Mehdi, Haider , Zhu, Xiaodong , Kerchner, Laurie J. , Sanyal, Shamarendra, Viswanathan, Prakash C., Pfahnl, Arnold , Shang, Lijuan L., Madhusudanan, Mohan, Baty, Catherine J. , Lagana, Stephen M. , Gutmann, Rebecca, Ackerman, Michael J. , McNamara, Dennis M. , Dudley, Samuel C. , Aleong, Ryan G. , Weiss, Raul , London, Barry

Mayo Clinic

Circulation | October 29, 2007 | Volume: 116 | Issue: 20 | Pages: 2260-2268

10.1161/circulationaha.107.703330 | PMID 17967977 Get It

Background— Brugada syndrome is a rare, autosomal-dominant, male-predominant form of idiopathic ventricular fibrillation characterized by a right bundle-branch block and ST elevation in the right precordial leads of the surface ECG. Mutations in the cardiac Na + channel SCN5A on chromosome 3p21 cause ≈20% of the cases of Brugada syndrome; most mutations decrease inward Na + current, some by preventing trafficking of the channels to the surface membrane. We previously used positional cloning to identify a new locus on chromosome 3p24 in a large family with Brugada syndrome and excluded SCN5A as a candidate gene. Methods and Results— We used direct sequencing to identify a mutation (A280V) in a conserved amino acid of the glycerol-3-phosphate dehydrogenase 1–like ( GPD1-L ) gene. The mutation was present in all affected individuals and absent in >500 control subjects. GPD1-L RNA and protein are abundant in the heart. Compared with wild-type GPD1-L, coexpression of A280V GPD1-L with SCN5A in HEK cells reduced inward Na + currents by ≈50% ( P <0.005). Wild-type GPD1-L localized near the cell surface to a greater extent than A280V GPD1-L. Coexpression of A280V GPD1-L with SCN5A reduced SCN5A cell surface expression by 31±5% ( P =0.01). Conclusions— GPD1-L is a novel gene that may affect trafficking of the cardiac Na + channel to the cell surface. A GPD1-L mutation decreases SCN5A surface membrane expression, reduces inward Na + current, and causes Brugada syndrome.
Cardiotrophin-1 Stimulation of Cardiac Fibroblast Growth
Tsuruda, Toshihiro , Jougasaki, Michihisa , Boerrigter, Guido, Huntley, Brenda K., Chen, Horng H. , D’Assoro, Antonino B. , Lee, Shang C., Larsen, Amy, Cataliotti, Alessandro , Burnett, John C.

Mayo Clinic

Circulation Research | July 28, 2002 | Volume: 90 | Issue: 2 | Pages: 128-134

10.1161/hh0202.103613 | PMID 11834704 Get It

Cardiotrophin-1 (CT-1), a member of the interleukin-6 superfamily, and endothelin-1 (ET-1) are potent hypertrophic factors in cardiomyocytes. Although CT-1 and ET-1 gene expression in the heart is upregulated in experimental heart failure, their role in the activation of the cardiac fibroblast is unknown. This study was designed to identify the presence and action of CT-1 and its receptor complex, glycoprotein130 (gp130) and leukemia inhibitory factor (LIF) receptor, on cardiac fibroblast growth in cultured adult canine cardiac fibroblasts. In addition, we investigated the interaction between CT-1/gp130/LIF receptor and ET-1/endothelin type A (ET A ) receptor axis. Immunohistochemistry was performed using the indirect immunoperoxidase method, while we assessed the cell cycle of cardiac fibroblasts by flow cytometry, DNA synthesis by [ 3 H]thymidine incorporation, and collagen synthesis by [ 3 H]proline incorporation, respectively. CT-1 and gp130/LIF receptor were widely present in the cytoplasm of the cardiac fibroblasts. Exogenous CT-1 markedly stimulated [ 3 H]thymidine and [ 3 H]proline incorporations ( P <0.01), with accumulation of cells in the S phase. Blockade of gp130 or LIF receptor inhibited basal growth as well as CT-1– or ET-1–stimulated cardiac fibroblast growth. The specific ET A receptor antagonist, BQ123, significantly inhibited CT-1–stimulated DNA synthesis. This study demonstrates that CT-1 and its receptors are present in cardiac fibroblasts. In addition, growth of these cells stimulated by endogenous and exogenous CT-1 requires gp130/LIF receptor as well as ET A receptor activation. We conclude that gp130/LIF receptor and ET A receptor activation are essential for cardiac fibroblast growth by CT-1 and that there is synergism with ET-1/ET A receptor axis.
Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure
Cataliotti, Alessandro , Boerrigter, Guido, Chen, Horng H. , Jougasaki, Michihisa , Costello, Lisa C., Tsuruda, Toshihiro , Lee, Shang-Chiun, Malatino, Lorenzo , Burnett, John C.

Mayo Clinic

Circulation | July 28, 2002 | Volume: 105 | Issue: 5 | Pages: 639-644

10.1161/hc0502.102962 | PMID 11827932 Get It

Background — Omapatrilat (OMA), a vasopeptidase inhibitor, simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase, which degrades vasodilatory factors (eg, ADM) and natriuretic peptides. Based on the beneficial cardiorenal and humoral properties of the natriuretic peptides, we hypothesized that an acute vasopeptidase inhibitor with or without diuretic would result in more favorable cardiorenal and hormonal actions than ACE inhibition plus diuretic (ACEI+D) in congestive heart failure. Methods and Results — We compared the actions of OMA alone and with diuretic (OMA+D) to ACEI+D in a model of pacing-induced congestive heart failure. OMA+D decreased pulmonary arterial and pulmonary capillary wedge pressures to a greater level than OMA alone or ACEI+D. Glomerular filtration rate was lower with ACEI+D than with either OMA group. Plasma renin activity and aldosterone immediately increased with ACEI+D, whereas OMA+D resulted in higher plasma renin activity and a delayed increase in aldosterone. OMA alone did not increase plasma renin activity and aldosterone, but resulted in a sustained increase in plasma adrenomedullin, with higher urinary atrial natriuretic peptide, adrenomedullin, and cGMP excretions than with ACEI+D. Conclusions — Acute administration of OMA with or without diuretic results in more favorable cardiorenal and humoral responses in experimental congestive heart failure than does ACEI+D. There is no acute activation of renin and aldosterone with OMA alone such as occurs with ACEI+D and OMA+D. Thus, OMA with or without a diuretic possesses beneficial cardiorenal and humoral actions comparable to those observed with ACEI+D that can be explained by potentiation of natriuretic peptides.